149 related articles for article (PubMed ID: 1791307)
1. CA 549 as a marker in breast cancer.
Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Dorsa R; Schwartz DC
Int J Biol Markers; 1991; 6(3):139-43. PubMed ID: 1791307
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients.
Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Schwartz DC
Tumour Biol; 1991; 12(2):82-90. PubMed ID: 2028182
[TBL] [Abstract][Full Text] [Related]
3. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
Nicolini A; Ferdeghini M; Colombini C; Carpi A
J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
Eskelinen M; Tikanoja S; Brown J
Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
[TBL] [Abstract][Full Text] [Related]
6. Correlation between changes in the tumour markers CA-M26 and CA-M29 and standard response evaluation in patients with metastatic breast cancer.
van der Gaast A; Hulshof C; Kok TC; van Loon E; Splinter TA
Eur J Cancer; 1993; 29A(6):870-3. PubMed ID: 8484981
[TBL] [Abstract][Full Text] [Related]
7. Circulating CA 549 and other associated antigens in breast cancer patients.
Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R
Oncology; 1994; 51(1):18-21. PubMed ID: 8265097
[TBL] [Abstract][Full Text] [Related]
8. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas.
Yedema CA; Kenemans P; Wobbes T; Thomas CM; Bon GG; Mulder C; Voorhorst FJ; Verstraeten AA; van Kamp GJ; Hilgers J
Tumour Biol; 1992; 13(1-2):18-26. PubMed ID: 1589694
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
10. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
[TBL] [Abstract][Full Text] [Related]
11. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer.
Rasoul-Rockenschaub S; Zielinski CC; Kubista E; Vavra N; Pospischil E; Staffen A; Czerwenka K; Aiginger P; Spona J
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1067-72. PubMed ID: 2759162
[TBL] [Abstract][Full Text] [Related]
13. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
Steger GG; Mader R; Derfler K; Moser K; Dittrich C
Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251
[TBL] [Abstract][Full Text] [Related]
14. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
Safi F; Kohler I; Röttinger E; Beger H
Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
[TBL] [Abstract][Full Text] [Related]
15. Serum (circulating) tumor markers for breast cancer.
Hayes DF
Recent Results Cancer Res; 1996; 140():101-13. PubMed ID: 8787054
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
[TBL] [Abstract][Full Text] [Related]
17. CA 72-4 serum marker--a new tool in the management of carcinoma patients.
Guadagni F; Roselli M; Cosimelli M; Ferroni P; Spila A; Cavaliere F; Casaldi V; Wappner G; Abbolito MR; Greiner JW
Cancer Invest; 1995; 13(2):227-38. PubMed ID: 7874576
[TBL] [Abstract][Full Text] [Related]
18. CA 549 and SP2: new tumor markers in breast cancer.
Torres M; Jiménez-Heffernan A; García A; Valverde A; Mateo A
Int J Biol Markers; 1990; 5(2):97-8. PubMed ID: 2283484
[No Abstract] [Full Text] [Related]
19. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.
Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F
Eur J Cancer; 1995 Sep; 31A(10):1615-21. PubMed ID: 7488411
[TBL] [Abstract][Full Text] [Related]
20. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
